Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

China maps a decade of heart valve care for its elderly

NCT ID NCT07816146

Knowledge-focused Sponsor: Yongjian Wu, MD, PhD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are running a national registry of hospitalized patients aged 60 and older who have moderate or severe heart valve disease. The study records the type of valve problem, symptoms, other conditions, treatments received, and complications. By comparing this group with patients enrolled in the China-DVD study in 2016, the team aims to show how valve disease and its management are changing and which factors shape outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the registry maps how valve disease and its treatment change over time, hospitals could tailor care for older patients more precisely and spot gaps in who gets surgery or catheter-based procedures.
What could go wrong
A registry observes routine care rather than testing a treatment, so it cannot prove what works. Findings may reflect only the hospitals that take part and may not apply to other settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 6,612 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This project is scheduled to be implemented from September to December 2026. It will consecutively enroll hospitalized patients with moderate and severe valvular heart disease across the original 69 national research centers of China-DVD, with the research protocol and definitions fully consistent with those in 2016.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Hospitalized patients over 60 years old meet one of the following conditions. 1、 moderate or above valvular heart disease as defined by echocardiography: One of the following criteria * (1)Mitral stenosis : Valve area ≤1.5 cm², or mean pressure gradient ≥10 mmHg. * (2)Mitral regurgitation : Moderate and above regurgitation, or regurgitant jet width ≥ 3 mm, or regurgitant volume per beat ≥ 30 ml, or regurgitant jet area/left atrial area \> 20%; or effective regurgitant orifice area (EROA) ≥ 20 mm² * (3)Aortic stenosis : Moderate and above, mean pressure gradient ≥ 20 mmHg, or peak jet velocity ≥ 3 m/s, or valve area ≤ 1.5 cm² * (4)Aortic regurgitation : Moderate and above regurgitation, or regurgitant jet width ≥ 3 mm, or regurgitant volume per beat ≥ 30 ml, or regurgitant fraction ≥ 30%, or jet width occupying ≥ 25% of the left ventricular outflow tract, or effective regurgitant orifice area (EROA) ≥ 10 mm² * (5)Tricuspid stenosis : Moderate and above * (6)Tricuspid regurgitation : Moderate and above regurgitation, or jet area ≥ 5 cm² * (7)Pulmonary stenosis : Moderate and above * (8）Pulmonary regurgitation : Moderate and above regurgitation 2 、Previous history of cardiac valve surgery or interventional therapy (dilation, valvuloplasty, valve replacement) 3、Diagnosed with infective endocarditis Exclusion Criteria: Patients unwilling to accept registration and follow-up; * Patients with mental illness who cannot cooperate with information collection and follow-up Patients have been enrolled in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart valve diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart valve disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart valve diseases Moderate to severe valve disease in the elderly

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fuwai Hospital, National Center for Cardiovascular Diseases，Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, 100037, China

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.